Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps

被引:52
作者
Ong, Christine T.
Tessier, Pamela R.
Li, Chonghua
Nightingale, Charles H.
Nicolau, David P. [1 ]
机构
[1] Hartford Hosp, Ctr Antiinfect Res & Dev, Hartford, CT 06102 USA
[2] Hartford Hosp, Div Infect Dis, Hartford, CT 06102 USA
关键词
pseudomonas; efflux pumps; pharmacodynamics;
D O I
10.1016/j.diagmicrobio.2006.06.014
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
To identify the optimal pharmacodynamic exposures of meropenem, imipenem, and cefepime, and the emergence of resistance in vivo for Pseudomonas aeruginosa overexpressing MexA-MexB-OprM efflux pumps, we used the murine thigh model. Mice were challenged with P. aeruginosa isolates: PAO1 (K767 wild type), K767+ (MexA-MexB-OprM efflux mutant), and AK767 (knockout strain). Efficacy (A log colony-forming unit [CFU]) was determined at various exposures of %T > MIC at both standard (10(5) CFU/thigh) and high (10(7) CFU/thigh) inoculums. At 10(5) CFU/thigh, meropenem and imipenem produced a maximal activity against PAO1 (-2.82, -1.88) and K767+ (-2.24, -2.68) at 40%T > MIC; cefepime at 70%T > MIC produced a comparable kill (-2.74 and -2.19, respectively). Similar magnitudes of kill were observed at the 10(7) inocula. Except for AK767 with cefepime, no development of resistance emerged at various %T > MIC. I agents exhibited reduced activity against Delta K767. Delta K767 cefepime-resistant strains were isolated up to 100%T > MIC. The overexpression of MexA-MexB-OprM efflux pumps did not result in the loss of efficacy of the antibiotics tested regardless of the amount of bacterial inocula; however, their presence also did not lead to increased selection for resistance. The effects of efflux mechanisms on beta-lactam agents in vivo warrant further research. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:153 / 161
页数:9
相关论文
共 26 条
[1]   The role of multidrug efflux pumps in the antibiotic resistance of Pseudomonas aeruginosa and other gram-negative bacteria -: Insights from the society of infectious diseases pharmacists [J].
Aeschlimann, JR .
PHARMACOTHERAPY, 2003, 23 (07) :916-924
[2]  
[Anonymous], 2003, NCCLS Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, V6th
[3]   Emergence of antibiotic-resistant Pseudomonas aeruginosa:: Comparison of risks associated with different antipseudomonal agents [J].
Carmeli, Y ;
Troillet, N ;
Eliopoulos, GM ;
Samore, MH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (06) :1379-1382
[4]  
CHO D, 1999, 39 INT C ANT AG CHEM
[5]   INTERRELATIONSHIP BETWEEN PHARMACOKINETICS AND PHARMACODYNAMICS IN DETERMINING DOSAGE REGIMENS FOR BROAD-SPECTRUM CEPHALOSPORINS [J].
CRAIG, WA .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1995, 22 (1-2) :89-96
[6]   Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men [J].
Craig, WA .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) :1-10
[7]  
Cunha Burke A, 2002, Semin Respir Infect, V17, P231, DOI 10.1053/srin.2002.34689
[8]   High-performance liquid chromatographic assay for meropenem in serum [J].
Elkhaili, H ;
Niedergang, S ;
Pompei, D ;
Linger, L ;
Leveque, D ;
Jehl, F .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1996, 686 (01) :19-26
[9]   INTEGRATION OF PHARMACOKINETICS AND PHARMACODYNAMICS OF IMIPENEM IN A HUMAN-ADAPTED MOUSE MODEL [J].
FLUCKIGER, U ;
SEGESSENMANN, C ;
GERBER, AU .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (09) :1905-1910
[10]   IN-VIVO AND IN-VITRO STUDY OF SEVERAL PHARMACODYNAMIC EFFECTS OF MEROPENEM [J].
FUENTES, F ;
MARTIN, MM ;
IZQUIERDO, J ;
GOMEZLUS, ML ;
PRIETO, J .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1995, 27 (05) :469-474